(Frankfurt) A booster dose of the COVID-19 vaccine developed by the Pfizer-BioNTech alliance is 95.6% effective against symptomatic forms of the disease, according to a study by the two laboratories published on Thursday.
The phase 3 clinical trial, carried out on “10,000 people over 16 years of age”, shows “a relative efficacy of 95.6%” and “a favorable safety profile”, according to a press release.
“These are the first results of efficacy of a randomized trial for a booster of the COVID-19 vaccine,” said the two companies.
This study was carried out even though “the Delta variant was the main strain” circulating during this period.
“These results demonstrate once again the usefulness of the recalls in our efforts to protect the population against this disease,” said Albert Bourla, CEO of Pfizer, quoted in the press release.
The median age of participants was around 53 years.
These results will be submitted to regulatory authorities “as soon as possible”, they added.
Several countries have already authorized the administration of a booster dose against the coronavirus to boost the immunity of those vaccinated, which seems to decline after several months, according to some studies.
In the United States, experts from the American Medicines Agency (FDA) have been recommending a third dose of Pfizer-BioNTech since the end of September for certain populations at risk, such as those over 65.
“The available data suggest a declining immunity in certain fully vaccinated populations”, recently justified the acting chief of the FDA, Janet Woodcock.
In Europe, the Medicines Agency (EMA) approved the principle of a third dose of Pfizer-BioNTech for people over 18 years of age at the beginning of October, leaving the States with a more precise choice of eligible populations.
France, for example, has started administering this booster dose to certain categories of the population: the oldest (six months after their vaccination) and people with weakened immune systems.
Other governments have gone further: in Israel, the third dose is available from the age of 12, five months after vaccination.
The subject of the third dose has, however, revived the issue of inequalities between rich and poor countries, while access to the first dose of vaccine remains very limited in certain regions of the world, particularly in Africa. Especially since two doses also protect very effectively against severe forms of the disease.